tiprankstipranks
Lumos Pharma downgraded to Neutral from Buy at H.C. Wainwright
The Fly

Lumos Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Lumos Pharma (LUMO) to Neutral from Buy with a price target of $4.25, down from $28, after the company entered into a definitive merger agreement whereby Double Point Ventures will acquire 100% of Lumos’ outstanding shares of common stock at a price of $4.25 per share in cash.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App